How does space promote science education

Jason and mia are both running in a race. as they approach the finish line, you being the physicist that you are decide to time how long it takes them to reach the end of the race. when you start your stop watch (you can take this as time t = 0 s) you notice that mia is an unknown distance d ahead of jason and both are moving with the same initial velocity v_0. you also notice that jason is accelerating at a constant rate of a_j, while mia is deaccelerating at a constant rate of -a_m. jason and mia meet each other for the first time at time t = t_1. at this time (t = t_1) jason's velocity is two times that of mia's velocity, meaning v_j (t_1) = 2v_m (t_1). a) draw the position vs. time graph describing mia's and jason's motion from time t = 0 to time t = t_1. clearly label your axes and initial conditions on your graph. b) draw the velocity vs. time graph describing mia and jason's motion from time t = 0s to time t = t_1. clearly label your axes and initial conditions on your graph. c) how long from when the stop watch was started at t = 0s did it take mia and jason to meet? express your answer in terms of know quantities v_0, a_m, and a_j. d) when the stop watch started at time t = 0s, how far apart, d, were mia and jason? express your answer in terms of know quantities v_0, a_m, and a_j.

Does work output exceed work input when a machine is used? a) yes, it does, as machines create energy. b) it depends on the type of machine used. c) no, it doesn’t, as machines are inefficient. d) no, it doesn’t, as machines cannot create energy.

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience. b. report the adverse drug experience to the irb only if there are several other occurrences. c. report the adverse drug experience as part of the continuing review report. d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.